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In 2015, there were approximately 40,000 new HIV diagnoses in the United States. Pre-
exposure prophylaxis (PrEP) is an effective strategy that reduces the risk of HIV acquisition;
however, uptake among those who can benefit from it has lagged. In this study, we 1) com-
pared the characteristics of patients who were prescribed PrEP with individuals newly diag-
nosed with HIV infection, 2) identified the specialties of practitioners prescribing PrEP, 3)
identified metropolitan statistical areas (MSAs) within the US where there is relatively low
uptake of PrEP, and 4) reported median amounts paid by patients and third-party payors for
PrEP.
Methods and findings
We analyzed prescription drug claims for individuals prescribed PrEP in the Integrated Data-
verse (IDV) from Symphony Health for the period of September 2015 to August 2016 to
describe PrEP patients, prescribers, relative uptake, and payment methods in the US. Data
were available for 75,839 individuals prescribed PrEP, and findings were extrapolated to
approximately 101,000 individuals, which is less than 10% of the 1.1 million adults for whom
PrEP was indicated. Compared to individuals with newly diagnosed HIV infection, PrEP
patients were more likely to be non-Hispanic white (45% versus 26.2%), older (25% versus
19% at ages 35–44), male (94% versus 81%), and not reside in the South (30% versus 52%
reside in the South).Using a ratio of the number of PrEP patients within an MSA to the num-
ber of newly diagnosed individuals with HIV infection, we found MSAs with relatively low
uptake of PrEP were concentrated in the South. Of the approximately 24,000 providers who
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prescribed PrEP, two-thirds reported primary care as their specialty. Compared to the types
of payment methods that people living with diagnosed HIV (PLWH) used to pay for their anti-
retroviral treatment in 2015 to 2016 reported in the Centers for Disease Control and Preven-
tion (CDC) HIV Surveillance Special Report, PrEP patients were more likely to have used
commercial health insurance (80% versus 35%) and less likely to have used public health-
care coverage or a publicly sponsored assistance program to pay for PrEP (12% versus
45% for Medicaid). Third-party payors covered 95% of the costs of PrEP. Overall, we esti-
mated the median annual per patient out-of-pocket spending on PrEP was approximately
US$72. Limitations of this study include missing information on prescription claims of
patients not included in the database, and for those included, some patients were missing
information on patient diagnosis, race/ethnicity, educational attainment, and income (34%–
36%).
Conclusions
Our findings indicate that in 2015–2016, many individuals in the US who could benefit from
being on PrEP were not receiving this HIV prevention medication, and those prescribed
PrEP had a significantly different distribution of characteristics from the broader population
that is at risk for acquiring HIV. PrEP patients were more likely to pay for PrEP using com-
mercial or private insurance, whereas PLWH were more likely to pay for their antiretroviral
treatment using publicly sponsored programs. Addressing the affordability of PrEP and oth-
erwise promoting its use among those with indications for PrEP represents an important
opportunity to help end the HIV epidemic.
Author summary
Why was this study done?
• Pre-exposure prophylaxis (PrEP) is an effective biomedical prevention strategy that
reduces the risk of HIV acquisition.
• However, uptake of this intervention among those who can benefit from it most has
lagged.
• Prior studies lack information about PrEP patients’ race/ethnicity, geographic distribu-
tions at the metropolitan statistical area (MSA) level, sex, educational attainment,
income, and patient and insurance payments in the United States.
What did the researchers do and find?
• We analyzed a large, nationally representative prescription claims database from Sym-
phony Health for the period of September 2015 to August 2016 in the United States.
• Compared to individuals with newly diagnosed HIV infection, PrEP patients were more
likely to be male, non-Hispanic White, and less likely to live in the South.
• MSAs with relatively low uptake of PrEP were concentrated in the South.
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• Compared to the types of payment methods that people living with diagnosed HIV
(PLWH) used to pay for their antiretroviral treatment, PrEP patients were more likely
to have used commercial health insurance and less likely to have used public healthcare
coverage or a publicly sponsored assistance program.
What do these findings mean?
• Many individuals who may benefit from being on PrEP are not currently receiving this
HIV prevention medication, and those prescribed PrEP have a significantly different
distribution of characteristics from the broader population that is at risk for acquiring
HIV.
• Third-party payors covered much of the costs. For many insured patients, insurance
coverage helped substantially offset the cost of PrEP medication.
Introduction
HIV remains a significant public health concern in the United States. Currently, an estimated
1.1 million individuals are living with HIV [1]. Although new HIV diagnoses declined 4.3%
from 41,942 in 2012 to 40,534 in 2016, progress has been uneven among different populations
and geographic locations in the US and 6 dependent areas. Of new diagnoses in 2016, nearly
70% occurred among men who have sex with men and were disproportionately concentrated
among minorities. The South accounted for both the highest proportion (51%) and rate (16.8
diagnoses per 100,000 population) of new diagnoses of HIV infection [2]. An antiretroviral
medication, Truvada, is commonly used for pre-exposure prophylaxis (PrEP) and is highly
effective in preventing HIV infections. PrEP treatment consists of daily use of tenofovir diso-
proxil fumarate (TDF) and a second medication, emtricitabine (FTC), in combination. Tru-
vada is currently one of two medications approved by the US Food and Drug Administration
(FDA) for PrEP. When used consistently and correctly by HIV-negative individuals at risk of
acquiring HIV, medication-based PrEP has been shown to reduce the risk of acquisition of
HIV infection through sex by more than 90% and by more than 70% among people who inject
drugs based on studies that used TDF alone [3]. However, the use of these highly effective
interventions by those who can most benefit from them has lagged [4]. Expanding access to
PrEP to more individuals at high risk for acquiring HIV represents an important opportunity
to help end the HIV epidemic in this country. The President’s Budget for fiscal year 2020
included a legislative proposal, “Ending the HIV Epidemic: A Plan for America,” which aims
to reduce new infections by 75% by 2025 and by 90% by 2030 [5]. The proposal’s 4 key strate-
gies are 1) diagnose all individuals with HIV as early as possible, 2) treat people with HIV rap-
idly and effectively to reach sustained viral suppression, 3) prevent new HIV transmissions by
using proven interventions, including PrEP and syringe service programs, and 4) respond
quickly to potential HIV outbreaks to get needed prevention and treatment services to people
who need them [6]. For instance, Health Resources and Services Administration (HRSA)
recently announced plans to devote Health Center resources to expand PrEP services to
selected health centers in jurisdictions where over half of all new infections occur [7].
The Centers for Disease Control and Prevention (CDC) estimated that in 2015, 1.1 million
HIV-negative adults had indications for PrEP and could have benefited from PrEP [8]. Prior
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studies have estimated the number of PrEP patients (9,375 with commercial insurance in
2014; 9,684 in 2015; 70,395 in 2017) [9,10,11]; however, little is known about PrEP uptake at
the metropolitan statistical area (MSA) level [8,11], characteristics of prescribers, or patient
and insurance payments for PrEP [12]. This information may help identify for whom and
where to focus efforts to increase use of PrEP and shed light on the cost of the medication for
payors and patients.
In this study, we examined a large, nationally representative prescription claims database to
1) compare the characteristics of patients who take PrEP (including age, race/ethnicity, geogra-
phy, and sex) to individuals with newly diagnosed HIV infection, 2) identify the specialties of
practitioners prescribing PrEP, 3) identify areas of the US at the MSA level where there is rela-




This study is reported as per the Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guidelines (S1 Text). To identify PrEP prescriptions, we used patient-
linked claims from September 2015 through August 2016 from the Integrated Dataverse (IDV)
prescription claims database produced by Symphony Health. The IDV contains longitudinal
data that capture adjudicated prescription, medical, and hospital claims across the US for all
payment types, including commercial plans, Medicare Part D, cash, assistance programs, and
Medicaid. The IDV contains over 10 billion deidentified prescriptions claims linked to over
280 million unique patients with an average of 5 years of prescription drug history. These pre-
scription drug claims are linked to hospital and physician practices claims with medical proce-
dure (i.e., CPT, HCPCS) and diagnosis codes (ICD- 9/10) for nearly 180 million patients. The
full database includes claims from over 65,000 pharmacies, 1,500 hospitals, 800 outpatient
facilities, and 80,000 physician practices across the US, capturing approximately 75% of the
total prescriptions dispensed in the US. The distribution of Symphony Health patients across
census regions is very similar to that of the US population according to the US Census Bureau
(Table A in S1 Appendix). Although substantial in scope, the data from IDV represent a con-
venience sample of the overall universe of prescriptions in the US.
To define our patient population, we first took a subset of the IDV database of only those
patients with a prescription for the combination of FTC and TDF, or Truvada (TDF/FTC).
We then excluded patients who used any of the antiviral drugs lamivudine, efavirenz, zidovu-
dine, lopinavir/ritonavir, raltegravir, dolutegravir, darunavir, and ritonavir to remove patients
using TDF/FTC and the aforementioned drugs as part of a drug regimen to treat HIV or hepa-
titis B. We followed the same algorithm used in Wu and colleagues [10] to identify claims for
PrEP (Fig 1). An individual in the claims data was considered to be a PrEP patient if 16 years
old or older with at least one prescription for TDF/FTC and without diagnosis codes or pre-
scription claims of medication indicative of having HIV or hepatitis B infection. Lastly, we
excluded individuals who had been prescribed TDF/FTC for 30 days or less, the same algo-
rithm used in the indicator for the National HIV/AIDS Strategy for PrEP, and assumed that
they either used TDF/FTC for postexposure prophylaxis (PEP) or that they were not taking
PrEP effectively, as had been assumed in prior work [10]. The prespecified study plan is avail-
able in S2 Text. Following review of initial results, we carried out further non-prespecified
analyses to 1) compare the characteristics of patients prescribed PrEP to individuals with diag-
noses of new HIV infections, 2) use MSA as a more granular level of geography for patient
characteristics, and 3) calculate payments for PrEP by payor type.
PLOS MEDICINE Uptake of and spending on PrEP in the United States
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IDV data include geographic information for patient residence location at the US Census
Bureau region level, whereas practitioner practice location is available at the ZIP code level. A
patient can have multiple practitioners who prescribed PrEP, but we used only one practi-
tioner and the practitioner’s ZIP code information per patient. We assigned the ZIP code of
Fig 1. PrEP patient algorithm applied to IDV database, September 2015–August 2016. Dx, diagnosis; IDV,
Integrated Dataverse; PrEP, pre-exposure prophylaxis; Rx, prescription.
https://doi.org/10.1371/journal.pmed.1003072.g001
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the physician who had the largest number of claims for PrEP for a given patient to that
patient’s residence. We aggregated ZIP codes to the MSA level because this allowed us to
compare the number of individuals prescribed PrEP to the number of individuals with newly
diagnosed HIV infection, a number that is also available at the MSA level in CDC’s HIV Sur-
veillance Report [13]. We compared the characteristics of PrEP patients in IDV with those of
individuals with newly diagnosed HIV infection nationwide as reported in the CDC’s 2015
annual HIV Surveillance Report [13]. The latter represents individuals who might have
avoided HIV infection had they been using PrEP. We also used these data to approximate rela-
tive levels of geographic uptake of PrEP by generating a ratio of the number of PrEP patients
within an MSA (in the numerator) to the number of newly diagnosed individuals with HIV
(in the denominator).
Analysis
We calculated descriptive statistics at the national level for demographic characteristics avail-
able in the database (age, race and ethnicity, census region, sex, educational attainment, and
household income) for PrEP patients and compared these statistics using a chi-squared test
with the characteristics of diagnoses of new HIV infections found in CDC’s HIV Surveillance
Special Report 2015 [14]. We also compared age, race and ethnicity, and sex at the MSA level
between the 2 groups to find possible MSAs where there might similar or dissimilar demo-
graphic compositions using CDC’s HIV Surveillance Supplemental Report 2015 [15]. There
were missing data in the IDV for demographic characteristics provided in the IDV database
such as patient race and ethnicity (35.2% missing), household income (36.2%), and educa-
tional attainment (33.9%). The categories of missing or unknown were not included in the
chi-squared test. To confirm whether this analysis using IDV data is consistent with previous
work, we compared PrEP patients having commercial insurance in the IDV database to PrEP
patients in a prior analysis using the 2010–2014 MarketScan Commercial Claims and Encoun-
ters database [10]. This comparison showed similar demographics for commercially insured
PrEP patients in the IDV and MarketScan databases (Table B in S1 Appendix), except for geo-
graphic distribution.
We aggregated the number of PrEP patients by MSA (we only included 107 MSAs with
populations of 500,000 or greater in our analysis), which we linked to the ZIP code informa-
tion provided in the IDV database for the patient’s provider who prescribed PrEP, and
reported the 20 MSAs with the lowest and the 20 MSAs with the highest relative use of PrEP.
Relative use of PrEP is calculated using the ratio of PrEP patients (numerator) to the number
of individuals newly diagnosed with HIV infection in 2015 (denominator).
To calculate the median, average, 25th and 75th percentile payments made by patients and
third-party payors (commercial insurance, Medicaid [includes both fee-for-service and man-
aged care], Medicare, TRICARE, Gilead discount program, and other assistance) and the stan-
dard deviation for these payments, we first totaled payments by payor type in each month for
each patient. Both the patient and third-party payor categories were provided in the IDV data-
base. There were a small number of cases of multiple payors within the same patient-month
(1.2%). We were able to identify that a payment made by a secondary third-party payor cov-
ered the patient cost-sharing amount for the primary payment method (e.g., Gilead’s payment
canceled the patient payment for commercial insurance). We averaged these payment
amounts across all months of data available for each patient. These average payment amounts
were then multiplied by 12 to annualize the data. Finally, we calculated these statistics across
all patients by payor type using the annualized payment amounts. We annualized the data to
avoid giving greater weight to patients with more months of data. For those without insurance
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and with household incomes less than 500% of the federal poverty level calculated in 2015, Gil-
ead offers a medication assistance plan that provides free medication. Gilead also offers a pay-
ment assistance program to pay for health insurance copays up to US$3,600 annually. Because
PrEP patients may appear in more than one category of third-party payor, these categories are
not mutually exclusive. We compared the payment methods for PrEP purchases by PrEP
patients with the types of payment methods used by people living with diagnosed HIV
(PLWH) infection during 2015 and 2016 for antiretroviral medications in the past 12 months
using Table 2 in the CDC HIV Surveillance Special Report 2015 [14].
All data analyses were calculated using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA;
2016). Specific ethics approval was not required for this secondary data analysis.
Results
Characteristics of PrEP patients
A total of 75,839 individuals in the IDV database were prescribed PrEP during September
2015 through August 2016; this number assumes that the IDV database captures approxi-
mately 75% of the total prescriptions dispensed in the US. We then extrapolated to 100% of
total prescriptions dispensed, assuming the same prevalence of prescription among those
included in IDV as those excluded, and estimated that approximately 101,000 patients were
prescribed PrEP nationally. There are estimated to be 1.1 million adults in the US with an indi-
cation for PrEP [8], suggesting that fewer than 10% of those who could potentially benefit
from PrEP received the drug during the study period.
Comparing individuals prescribed PrEP in the IDV database to those with newly diagnosed
HIV infection in 2015, PrEP patients were more likely to be non-Hispanic white (45% versus
26.2%), be older (25% versus 19% at ages 35–44), be male (94% versus 81%), and not reside in
the South (30% versus 52% reside in the South) (Table 1). All differences were statistically sig-
nificant using a chi-squared test with a p-value less than 0.001. Supplemental information on
how PrEP patients differed from individuals with newly diagnosed HIV infection by age, race
and ethnicity, and sex at the MSA level is provided in Table B in S1 Appendix. These findings
may help identify populations where efforts to increase uptake of PrEP could be targeted.
Uptake of PrEP by MSA
The 20 MSAs ranked as having the lowest and highest amounts of uptake of PrEP are shown
in Table 2 (see Table D in S1 Appendix for relative uptake for the full list of 107 MSAs). Fig 2
depicts this information geographically with relative uptake of PrEP color coded by quintiles,
with red indicating MSAs with the lowest uptake of PrEP. The 3 MSAs with the lowest relative
uptake of PrEP are McAllen–Edinburg–Mission, TX (ratio of 0.10), Virginia Beach–Norfolk–
Newport News, VA–NC (0.15), and Baton Rouge, LA (0.18).
Specialties and locations of PrEP-prescribing practitioners
A total of 23,955 practitioners out of approximately 1.8 million prescribers in the IDV database
prescribed PrEP. Although a variety of specialties were reported for these practitioners, two-
thirds reported primary care (i.e., internal medicine, family medicine, and family practice) as
their specialty (Table E in S1 Appendix; Table F in S1 Appendix for the top 20 diagnoses for
PrEP patients; and Table G in S1 Appendix for the top 20 MSAs by number of PrEP-prescrib-
ing practitioners). Provider specialty is self-reported, and some of the categories may overlap
(e.g., family medicine and family practice).
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Paying for PrEP
On average, individuals prescribed PrEP used 1.013 (range: 1 to 3) different payment methods
to pay for PrEP each month. Payment methods included commercial health insurance, Medic-
aid, Medicare, TRICARE, Veterans Administration (VA), Gilead’s discount program, cash,
Table 1. Demographic characteristics of individuals prescribed PrEP in IDV database and adults and adolescents diagnosed with HIV infection reported to the
CDC in 2015.
Number of Individuals Prescribed PrEP,
September 2015–August 2016
% Number of Individuals with Newly
Diagnosed HIV Infection, 2015
% p-
Value���
Total 75,839 100.0 39,741 100.0
Age^ <0.001
13–14 Not Available 26 0.1
15–34 34,935 46.1 22,010 55.4
35–44 18,753 24.7 7,669 19.3
45–54 15,088 19.9 6,306 15.9
55–64 5,781 7.6 2,883 7.3
�65 1,282 1.7 847 2.1
Ethnicity <0.001
Black/African American 5,944 7.8 17,345 43.6
Hispanic/Latino 6,523 8.6 9,682 24.4
White/Caucasian 34,427 45.4 10,447 26.3
Other 2,230 2.9 2,267 5.7
Unknown 26,715 35.2 Not Available
Geography—Census Region <0.001
Midwest 12,298 16.2 5,198 13.1
Northeast 20,243 26.7 6,478 16.3
South 22,550 29.7 20,377 51.3
West 20,132 26.6 7,688 19.3
Other/unknown 616 0.8 Not Available
Sex <0.001
Male 71,349 94.1 32,306 81.3
Female 4,490 5.9 7,435 18.7
Educational Attainment N/A
HS graduate or less 13,447 17.7 Not Available
Some college 16,790 22.1 Not Available
Associate degree/bachelor
degree or more
19,885 26.2 Not Available
Unknown 25,717 33.9 Not Available
Household Income N/A
Under 30,000 4,571 6.0 Not Available
30,000–49,000 8,158 10.8 Not Available
50,000–74,000 11,412 15.1 Not Available
75,000–99,000 8,704 11.5 Not Available
100,000+ 15,523 20.5 Not Available
Unknown 27,471 36.2 Not Available
Source: Authors’ analysis of the IDV data from September 2015 to August 2016.
���p-value for chi-squared tests.
^Age categories for PrEP patients are 16–35, 36–45, 46–55, 55–65, over 65.
Abbreviations: CDC, Centers for Disease Control and Prevention; IDV, Integrated Dataverse; N/A, not applicable; PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1003072.t001
PLOS MEDICINE Uptake of and spending on PrEP in the United States
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003072 April 10, 2020 8 / 17
Table 2. Number of PrEP patients, number of newly diagnosed HIV infections in 2015, and ratio of relative uptake by MSA for the 20 MSAs with the lowest and
highest uptake.
MSA Number of PrEP
Patients
Number of People with Newly
Diagnosed HIV Infection, 2015
Ratio of Number of PrEP Patients to Number of
Newly Diagnosed HIV Infections
Ranking of
Ratio
Twenty MSAs by Lowest Uptake Lowest 20
MSAs
McAllen–Edinburg–Mission, TX 9 82 0.11 1
Virginia Beach–Norfolk–Newport
News, VA–NC
53 293 0.18 2
Baton Rouge, LA 54 265 0.20 3
Deltona–Daytona Beach–Ormond
Beach, FL
22 78 0.28 4
San Juan–Carolina–Caguas, PR 144 399 0.36 5
Palm Bay–Melbourne–Titusville, FL 21 57 0.37 6
Augusta–Richmond County, GA–
SC
41 104 0.39 7
Bakersfield, CA 49 121 0.40 8
Lakeland–Winter Haven, FL 43 106 0.41 9
Memphis, TN–MS–AR 127 312 0.41 10
Stockton–Lodi, CA 28 68 0.41 11
El Paso, TX 48 116 0.41 12
Jacksonville, FL 131 315 0.42 13
Youngstown–Warren–Boardman,
OH–PA
15 35 0.43 14
Columbia, SC 81 164 0.49 15
Greenville–Anderson–Mauldin, SC 39 78 0.50 16
Greensboro–High Point, NC 67 131 0.51 17
San Antonio–New Braunfels, TX 200 386 0.52 18
Richmond, VA 135 227 0.59 19
Fresno, CA 61 102 0.60 20
Twenty MSAs by Highest Uptake Highest 20
MSAs
Madison, WI 204 21 9.71 1
Seattle–Tacoma–Bellevue, WA 2,877 334 8.61 2
San Francisco–Oakland–Hayward,
CA
5,625 722 7.79 3
Boston–Cambridge–Newton, MA–
NH
2,876 456 6.31 4
Portland–Vancouver–Hillsboro,
OR–WA
897 165 5.44 5
Des Moines–West Des Moines, IA 169 32 5.28 6
Salt Lake City, UT 384 75 5.12 7
Minneapolis–St. Paul–
Bloomington, MN-WI
1,212 265 4.57 8
Albany–Schenectady–Troy, NY 223 50 4.46 9
Rochester, NY 375 87 4.31 10
Chicago–Naperville–Elgin, IL–IN–
WI
5,347 1,380 3.87 11
Providence–Warwick, RI–MA 405 107 3.79 12
Pittsburgh, PA 622 165 3.77 13
Boise City, ID 72 20 3.60 14
New York–Jersey City, NY–NJ–PA 12,402 3,563 3.48 15
(Continued)
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and other assistance programs. Most (80%) PrEP patients in the IDV database used commer-
cial health insurance, alone or in conjunction with other payment methods, to pay for PrEP
(Table 3), followed by patients with Gilead’s assistance program (12.51%), Medicaid (11.83%),
Medicare (4.25%), cash (3.76%), other assistance (2.20%), and TRICARE (0.56%). Patients can
have multiple third-party payors. Compared to the payment methods used by PLWH in 2015
and 2016 for antiretroviral medications, PrEP patients were more likely to use commercial or
private health insurance (80% for PrEP patients versus 35% for PLWH) and less likely to use
public insurance or assistance programs.
The estimated median annual per patient spending on PrEP medication was US$72 in out-
of-pocket spending for patients and US$17,496 across all third-party payors (see Table 4).
Commercial health insurance plans covered approximately 98% (US$17,568 per patient per
year) of the costs of TDF/FTC for their enrollees, a coverage amount similar to Medicaid
(>99%), Medicare (>99%), TRICARE (99%), and Gilead for those who qualify (>99%). For
patients with Medicare, the low median patient payment appears to be explained by the high
percentage (67%) of Medicare beneficiaries in this patient population who receive the Low-
Income Subsidy under the Medicare Part D prescription drug program. Approximately 15%
of commercially insured PrEP patients had cost sharing equal to or exceeding US$3,697 per
year (US$925 average yearly payment with commercial insurance; ±US$2,772 standard devia-
tion [see Table H in S1 Appendix]), or US$308 per month.
Discussion
In this study of a US prescription claims database for the period of September 2015 to August
2016, we found that less than 10% of individuals indicated for PrEP were prescribed PrEP, sug-
gesting that many people who might have benefited from PrEP were not receiving it. In 2016,
Black/African American and Hispanic/Latino individuals accounted for the highest rates of
diagnoses of HIV infection [2], but these groups accounted for low proportions (7.8% and
8.6%, respectively) of PrEP patients in our analysis. This disparity by race and ethnicity is con-
sistent with previous research [8,16]. We found that MSAs with low relative uptake of PrEP
tended to be concentrated in the South, which is also where the incidence of HIV is the highest
in the country [2]. Additional efforts could be employed to increase uptake of PrEP in these
populations and areas of the country. Some local and state government agencies have devel-
oped and implemented community outreach and social media campaigns that may contribute
to increased awareness and uptake of PrEP [16]. In New York, e.g., the health department in
2015 featured advertisements in subway stations, on Metropolitan Transportation Authority
Table 2. (Continued)
MSA Number of PrEP
Patients
Number of People with Newly
Diagnosed HIV Infection, 2015
Ratio of Number of PrEP Patients to Number of
Newly Diagnosed HIV Infections
Ranking of
Ratio
Durham–Chapel Hill, NC 279 81 3.44 16
Columbus, OH 826 240 3.44 17
San Jose–Sunnyvale–Santa Clara,
CA
534 156 3.42 18
Washington–Arlington–Alexandria,
DC–VA–MD–WV
3,941 1,233 3.20 19
Denver–Aurora–Lakewood, CO 789 272 2.90 20
Source: Authors’ analysis of the IDV data from September 2015 to August 2016 and the CDC’s 2015 annual HIV Surveillance Report. Abbreviations: CDC, Centers for
Disease Control and Prevention; IDV, Integrated Dataverse; MSA, metropolitan statistical area; PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1003072.t002
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(MTA) buses, and online [17]. Health departments in San Francisco, the District of Columbia,
and other cities have also launched campaigns involving promotion of PrEP [18]. In Florida,
the Department of Health planned to make PrEP available at no cost through county health
departments by the end of 2018 [19]. Similar efforts could be undertaken in other areas of the
South, given we found that PrEP uptake was relatively lower in the South.
Fig 2. Relative uptake of PrEP by MSA for MSAs with populations of 500,000 or greater. Source: Authors’ analysis of the IDV data from
September 2015 to August 2016 and CDC’s 2015 Annual HIV Surveillance Report. The authors used a shapefile, rather than a basemap, of the
US with state borders from the US Census Bureau, https://www.census.gov/geographies/mapping-files/time-series/geo/tiger-line-file.html. CDC,
Centers for Disease Control and Prevention; IDV, Integrated Dataverse; MSA, metropolitan statistical area; PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1003072.g002
Table 3. Payment methods of PrEP patients, September 2015 through August 2016, and type of health insurance of coverage for antiretroviral medications for
PLWH.
Payment Methods Number of PrEP
Patients
Proportion of All PrEP
Patients (%)
Proportion of Individuals Living with
Diagnosed HIV (%)
Commercial 60,580 79.88% 34.90%
Medicaid 8,970 11.83% 44.80%
Medicare 3,224 4.25% 27.50%
TRICARE/CHAMPUS or VA (VA not included in PrEP
patient data)
428 0.56% 4.80%
Gilead 9,487 12.51% n/a
Cash 2,851 3.76% n/a
Other assistance 1,672 2.20% n/a
Ryan White n/a n/a 44.90%
Other public insurance n/a n/a 12.50%
Insurance type unknown n/a n/a 1.50%
No health insurance or coverage n/a n/a 1.90%
Source: Authors’ analysis of the IDV data from September 2015 to August 2016.
Each payment method is not mutually exclusive; i.e., patients may use more than one type of payment method and appear in more than one row in this table. The
number of individuals prescribed PrEP in Table 3 adds up to more than 75,839. The percent of individuals prescribed PrEP does not sum to 100% for the same reason.
There are very few patients who are dually eligible for Medicare and Medicaid. Gilead is parsed out from “Other assistance.” “TRICARE” is parsed out from commercial
insurance. We identified 4 patients with payments for PrEP made by the VA and are not reporting on them due to the small sample size. Abbreviations: IDV,
Integrated Dataverse; PLWH, people living with diagnosed HIV; PrEP, pre-exposure prophylaxis; VA, Veterans Administration.
https://doi.org/10.1371/journal.pmed.1003072.t003
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We found that PrEP patients are more likely to pay for PrEP using commercial or private
insurance, which helped substantially offset the cost of TDF/FTC (median out-of-pocket pay-
ments for patients with commercial insurance were US$30 per month), whereas patients living
with HIV are more likely to pay for their antiretroviral treatment using public insurance (Med-
icaid and Medicare) or a publicly sponsored assistance program (Ryan White HIV/AIDS Pro-
gram). For PLWH who are uninsured or underinsured, the Ryan White HIV/AIDS Program
covers the costs of antiretroviral medication to treat HIV, among other HIV-related treatment
services, as a secondary payer but cannot pay for PrEP medications for HIV-negative individu-
als. Given that many individuals receiving antiretroviral medication are paying for this treat-
ment using payment sources other than private insurance, this indicates that many of those
who could benefit from taking PrEP may not be able to afford PrEP, since many of them
appear to not have private insurance coverage. Concerns related to cost and lack of insurance
or underinsurance can be a barrier to use of PrEP [16]. One study seemed to counter this
notion with its findings that between 50% to 75% of individuals indicated for PrEP have public
or private insurance to cover most PrEP care costs [12]. We were unable to ascertain the num-
ber of individuals with private insurance that does not cover TDF/FTC or the number of indi-
viduals who may forgo TDF/FTC treatment because of the level of patient cost sharing.
Regardless, even among those who have insurance that could cover the costs of PrEP, there

















Any Insurance 264,929 Patient $6 $0 $0 $72
TPP $1,458 $1,379 $1,498 >99% $17,496
Commercial 187,148 Patient $30 $0 $50 $360
TPP $1,464 $1,389 $1,509 98% $17,568
Medicaid 30,580 Patient $0 $0 $3 $0
TPP $1,468 $1,396 $1,483 >99% $17,616
Medicare 13,487 Patient $1 $0 $10 0% $12
Low-Income
Subsidy
10,185 Patient $0 $0 $4 0% $0
Other 3,302 Patient $74 $50 $474 5% $888
TPP $1,462 $1,379 $1,494 >99% $17,544
Tricare 2,013 Patient $20 $0 $24 $240
TPP $1,429 $1,358 $1,445 99% $17,148
Gilead 27,737 Patient $0 $0 $0 $0
TPP $75 $35 $1,480 >99% $900
Cash Only 118 Patient $1,791 $1,716 $1,945 $21,492
TPP $0 $0 $0 0% $0
Other
Assistance
3,281 Patient $0 $0 $0 $0
TPP $1,399 $74 $1,510 >99% $16,788
Source: Authors’ analysis of the IDV data from September 2015 to August 2016.
Notes: Each payment method category is not mutually exclusive, except for the category “Cash Only.” That is, patients may have more than one type of insurance and
appear in more than one row in this table. The exception is “Cash Only”; patients in this category only paid for PrEP using cash. The number of individuals prescribed
PrEP in Table 4 adds up to more than 75,839. The percent of individuals prescribed PrEP does not sum to 100% for the same reason. “TRICARE” is parsed out from
commercial insurance. We identified 4 patients with payments for PrEP made by the VA and are not reporting on them due to the small sample size. There are very few
patients in this database who are dually eligible for Medicare and Medicaid. Abbreviations: IDV, Integrated Dataverse; PrEP, pre-exposure prophylaxis; TPP, third-
party payor; VA, Veterans Administration.
https://doi.org/10.1371/journal.pmed.1003072.t004
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may still be perceived concerns about the affordability of PrEP given its price. It is also possible
that some individuals indicated for PrEP were not aware of the availability of the Gilead assis-
tance program, which might have lowered the cost of the medication for some of these
patients. In June 2019, the US Preventive Services Task Force (USPSTF) published a final rec-
ommendation statement on PrEP. The USPSTF recommends that clinicians offer PrEP to peo-
ple at high risk of HIV acquisition, giving this recommendation an A grade [20]. Under
current law, most private insurance plans are required to cover USPSTF Grade A and B rec-
ommendations with no out-of-pocket costs [21]. In order for this policy to affect uptake, it will
be important for high-risk individuals to be become aware that this is the case.
From a third-party payor perspective, given our estimate of the median annual cost of PrEP
to third-party payors (US$72 + U$17,496 = US$17,568), PrEP costs approximately 36% less
than the annual per-person cost of HIV treatment and care, previously estimated at US$27,461
(2016 US dollars) [22,23]. This comparison only includes the cost of medication for PrEP and
not the costs of other services associated with taking PrEP, including follow-up office visits
and laboratory tests that should be conducted every 3 months to screen for HIV, STDs, preg-
nancy for women who may become pregnant, and potential effects of the medication on kid-
neys [3]. However, even when including clinical costs, another study found PrEP to be highly
cost-effective for high-risk populations [24]. In June 2017, the US FDA approved production
of generic Truvada by Teva Pharmaceuticals as a component of an HIV treatment regimen
and as PrEP [25]. Generic Truvada is still not available in the US market [25], but Gilead Sci-
ences announced that Teva Pharmaceuticals will be able to launch a generic versions of Tru-
vada in the US on September 30, 2020 [26,27]. When the generic formulation becomes
available in the US, it is possible that the price for this drug may decrease, but generic manu-
facturers often hold exclusive rights for an initial period before competitors can also begin pro-
ducing the medication and drive down prices [25]. In Europe, several generic manufacturers
have received marketing approval from the European Medicines Agency for tenofovir diso-
proxil with emtricitabine (TDX/FTC), a bioequivalent to TDF/FTC [28].
Other barriers, beyond financial access, to uptake include low awareness of PrEP among
potential patients [29,30,31] and their practitioners [32,33,34]. Primary care providers most
frequently identified limited knowledge of PrEP and concerns regarding insurance coverage as
prescribing barriers [32]. Mistrust of the medical system and perceived discrimination can
also create barriers to accessing PrEP and other forms of HIV prevention [35,36].
Our study has some limitations and required several assumptions. First, we used claims
data for this analysis, which exclude uninsured individuals who acquired PrEP purely through
out-of-pocket spending. Given the cost of PrEP, this population would have likely had more
financial resources relative to those not acquiring PrEP. The extrapolated number of PrEP
patients assumes that the percentage of PrEP claims in the IDV database out of all possible
drug claims in the US is the same as the average percentage across all drugs in the database out
of all possible drug claims in the US (75%). Approximately 41.6% of the individuals identified
in the subset of the IDV database have prescription drug claims but are missing diagnosis
claims; we treated these individuals as not having HIV and/or hepatitis B. However, we were
able to exclude nearly everyone with HIV by excluding patients with non-Truvada antiretrovi-
ral medication. Information on race and ethnicity, educational attainment, and income were
missing for 34%–36% (depending on the variable) of PrEP patients in IDV. Although guide-
lines only recommend PrEP for patients 18 years or older, we included patients 16 years or
older because age was provided as a categorical variable in the data we received (for privacy
purposes), with the first relevant age category being 16 to 20 years old. We used 1 year of data
to identify PrEP patients, but it is possible that a patient may have had an HIV or hepatitis B
diagnosis in prior years, which would misattribute some number of people with HIV and/or
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hepatitis B infection as PrEP users. We used the number of newly diagnosed HIV cases in the
denominator, which may be affected by the regional variation in the rate of diagnostic testing
and delays between HIV infection and diagnosis [37]. We also assumed that the demographic
and geographic characteristics of individuals with newly diagnosed HIV infection were similar
to those at risk for HIV infection (i.e., people indicated for PrEP) because those with diagnosed
with HIV were likely those who were most at risk of HIV infection given they actually acquired
HIV. Ideally, we would have used estimates of the number of individuals at risk of HIV infec-
tion by MSA in 2016 in the denominator, but no known estimates exist. Given that we do not
have access to medical claims in IDV, we were not able determine the length of time individu-
als may have been living with HIV prior to receiving a diagnosis. Finally, cases of HIV infec-
tion by victims of rape or assault, which represent a relatively small proportion of all
individuals who acquire HIV [38], are unlikely to affect our estimates of relative uptake of
PrEP.
We identified nearly 101,000 individuals prescribed PrEP during September 2015 through
August 2016, which is fewer than 1 in 10 of those indicated for PrEP. Compared to individuals
newly diagnosed with HIV in 2015, PrEP patients were more likely to be male, be non-His-
panic white, be older, have commercial insurance, and live in regions other than the South.
Many individuals who may benefit from being on PrEP are not currently receiving this HIV
prevention medication, and those prescribed PrEP have a significantly different distribution of
characteristics from the broader population that is at risk for acquiring HIV. Median monthly
patient cost sharing varied from US$0 for Medicaid beneficiaries to US$1,791 for those paying
with cash.
Our findings indicate that many individuals who could potentially benefit from being on
PrEP are not currently receiving this medication. Addressing the affordability of PrEP and
otherwise promoting its use among those with indications for PrEP represents an important
opportunity to help end the HIV epidemic.
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